Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it has commenced a Phase 1 first-in-human clinical trial (CITADEL-123) of 123I-ATT001, its Iodine-123 labelled PARP inhibitor, in patients with recurrent glioblastoma. The trial opened at University College London Hospitals (UCLH) and will assess the safety and early efficacy of Ariceum's radiotherape

BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF) has commenced enrollment in the United States. BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of t

HYD LLC for Cancer Research and Drug Development (HYD or the Company) today announces two independent review papers in Nutrients -  Deuterium-Depleted Water in Cancer Therapy: A Systematic Review of Clinical and Experimental Trials and Frontiers in Pharmacology – The Biological Impact of Deuterium and Therapeutic Potential of Deuterium-depleted Water. These review papers culminate 30 years of research into Deuterium Depleted Water (DDW) and set out the role of Deuterium-Depleted Wa

OS Therapies, Inc., a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced positive data from a Phase 1 clinical trial of OST-HER2 in patients with HER2-expressing solid tumors in breast cancer and other cancers. Additionally, the Company announced positive preclinical efficacy data for OST-HER2 in multiple models of breast cancer. The FDA has granted Rare Pediatric Disease Designat

OSE Immunotherapeutics SA, today announced positive topline results from its Phase 2 CoTikiS randomized, double-blind, placebo-controlled proof-of-concept study with Lusvertikimab, a pure IL-7 receptor antagonist, demonstrating significant efficacy results as measured by improvement in Modified Mayo Score** (at Week 10, the primary endpoint of the induction phase of treatment). A favorable safety profile was observed during both the induction phase and the 6-month open-label extension phase o

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in clinical trial of the Company's novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 in the United States. ICP-332 is a potent and selective TYK2 inhibitor. ICP-332 achieved multiple efficacy endpoints in the China Phase II study for the treatment of patients with moderate-to-severe atopic dermatitis (AD), demonstr

 Xavo, a leading provider of innovative software solutions for Life Sciences R&D, proudly announces Plexium as its latest esteemed client. - “We are thrilled to welcome Plexium to the Xavo family. The collaboration between the two companies marks a significant milestone in Xavo’s journey. We stay committed to deliver cutting-edge technology, tailored to meet the evolving needs of R&D labs worldwide,” says Gabriel Petrescu, Xavo’s VP of Business Dev

Currax Pharmaceuticals LLC today announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union (EU) and European Union Economic Areas (EEA). The new site doubles the current production capacity of CONTRAVE/MYSIMBA and ensures continuity of supply, and the site has capacity to increase production when needed. An application to the U.S. Food & Drug Administration (FDA) for approval of this additional site is scheduled for Q3 2024. As